Cardium Therapeutics is a San Diego based health sciences and regenerative medicine company that has carefully diversified itself with a strategy designed to provide short-term, mid-term, and long-term growth and revenue. In so doing, they have successfully positioned themselves in several markets, much like a rocket with multiple stages timed for continuous acceleration.
Immediate revenue is provided through Cardium's To Go Brands subsidiary, acquired in 2012, which markets and sells a growing portfolio of over 25 healthy lifestyle products, including nutraceutical powder mixes and supplements designed for both convenience and health of active lifestyle consumers. Their product line contains 100% natural antioxidant-rich drink mixes with organic ingredients, in convenient stick packs, designed to pour directly into a water bottle, mix packages for home use, and capsule-based dietary supplements. It's a big and fast growing market, projected by some to top $200 billion over the next several years, and should continue to provide Cardium with an important source of revenue to support their other developments.
Further down the timeline, but not too far, is Excellagen, Cardium's FDA-cleared wound treatment gel that has already been proven to significantly aid healing for many types of wounds, including diabetic foot ulcers. The company is in the final commercialization stages for Excellagen, and has been awarded ISO certification to market and sell Excellagen in the U.S. The company has also advanced international registrations. The ease of use and effectiveness of this new treatment, together with the fact that it has broad application potential, bodes well for future revenue.
And finally there is Generx, an important DNA-based angiogenic growth factor therapeutic, designed to actively increase blood flow around the heart for the treatment of heart disease. The product is qualitatively different than traditional drugs for treating heart disease, drugs which only address the pain or future blockages. It is still under development, but Cardium has successfully initiated a phase 3 registration study, and has published important Generx findings in the peer-reviewed journal Human Gene Therapy Methods.
For additional information, visit CardiumTHX.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net